Moxifloxacin (as HCl) 400mg/250mL; soln for IV infusion; latex- and preservative-free. Moxifloxacin inhibits topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial ...

The activity, pharmacokinetics, pharmacodynamics, efficacy, safety, drug interactions, and dosage and administration of moxifloxacin are reviewed. Moxifloxacin is an oral 8-methoxyquinolone ...

It alerts doctors and patients about drug effects that may be dangerous. Moxifloxacin oral tablet is available as a brand-name drug and a generic drug. Brand name: Avelox. Moxifloxacin comes as a ...

904 patients (51.7%) received moxifloxacin and 846 patients (48.3%) one of the macrolides. Demographic data were comparable in the two treatment groups. Slightly more than half of the patients ...

Perspective from Randall J. Olson, MD “The main take-home message from the study is to inject enough moxifloxacin to kill sensitive bacteria, either by injecting 0.5 mL of moxifloxacin 0.1% ...

Moxifloxacin is currently approved in more than 100 countries, including the United States, as a treatment for bacterial respiratory infections, such as bronchitis, sinusitis and pneumonia. Share ...

Early-phase and preclinical studies suggest that moxifloxacin-containing regimens could allow for effective 4-month treatment of uncomplicated, smear-positive pulmonary tuberculosis. We conducted ...

Tuberculosis regimens that are shorter and simpler than the current 6-month daily regimen are needed. We randomly assigned patients with newly diagnosed, smear-positive, drug-sensitive ...

To report a newly recognized adverse effect of oral moxifloxacin. In five patients, a uveitis-like episode followed oral moxifloxacin therapy, afterwards they experienced photophobia. At slitlamp ...